



It's a Done Deal

\$4,507,000



Registered Direct  
Sole Placement Agent  
NOVEMBER 2023

## ROTH MKM Acted as Sole Placement Agent for Biofrontera Inc. (Nasdaq: BFRI) in its \$4.5 Million Registered Direct Offering

**For more information  
please contact:**

### **Investment Banking**

**Benjamin Bowen**  
Managing Director  
Investment Banking  
(646) 716-3607  
[bbowen@roth.com](mailto:bbowen@roth.com)

**Aparna Beeram**  
Senior Vice President  
Investment Banking  
(646) 358-1912  
[abeeram@roth.com](mailto:abeeram@roth.com)

### **Equity Capital Markets**

**Aaron Gurewitz**  
President & Head of  
Investment Banking  
(949) 720-5703  
[agurewitz@roth.com](mailto:agurewitz@roth.com)

### **Transaction Information**

Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatologic products, entered into a securities purchase agreement with a certain institutional investor, pursuant to which the Company agreed to issue and sell to the investor an aggregate of 1,205,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase an aggregate of up to 1,807,000 shares of Common Stock, at an exercise price of \$3.55 per share of Common Stock. The warrants are exercisable immediately upon issuance and will expire five years following the date of issuance. The Company also agreed to adjust the strike price of 385,236 outstanding warrants held by the investor to \$3.55. The offering closed on November 2, 2023.

ROTH MKM acted as sole placement agent for the offering.

### **About Biofrontera Inc.**

**Nazan Akdeniz**  
COO &  
Managing Director  
Equity Capital Markets  
(949) 720-5740  
[nakdeniz@roth.com](mailto:nakdeniz@roth.com)

**Lou Ellis**  
Managing Director  
Equity Capital Markets  
(949) 720-5739  
[lellis@roth.com](mailto:lellis@roth.com)

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of products for the treatment of dermatologic conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For further information about the Company, please visit [www.Biofrontera-us.com](http://www.Biofrontera-us.com)

*(Source: Company Website 11.16.23)*

#### **About ROTH MKM**

ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on Roth, please visit [www.roth.com](http://www.roth.com).

---

[About ROTH MKM](#) | [Investment Banking](#) | [Capital Markets](#) | [Institutional Sales & Trading Research](#) | [Corporate Services](#) | [Corporate Access & Conferences](#) | [Press Room](#)

---

Date of Announcement: 11.21.23

The material, information and facts discussed in this announcement other than the information regarding ROTH MKM and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of Roth. Copyright 2023.

**Roth Capital Partners, LLC**

888 San Clemente Drive, Newport Beach CA 92660 | Member SIPC/FINRA | [www.roth.com](http://www.roth.com)

